focus -WSS

focus

author：entertainment 2025-09-27 23:51:58 - browse：8517

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Apple is now the first public company to be valued at $3 trillion

entertainment

WSS

United colonoscopy coverage change 'may cost lives,' doctors say

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How one medical school became remarkably diverse

Malaria cases in Florida and Texas: Here’s what you need to know

FDA approval of Sarepta Duchenne genetic therapy gives me hope

focus

focus

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Liver decline slowed by off

Drug repurposing or repositioning? The language matters

FDA poised to publish guidelines for clinical trial diversity

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Affirmative action in medical school literally saved lives

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

In age of alternative facts, a scholarly course on calling out crap

Fentanyl is making it harder to start addiction treatment

Wikipedia

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

H5N1 virus can be tracked in retail milk, scientists say

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ASCO eve: Let’s set the table for this year's meeting

George Santos makes 1st court appearance after pleading not guilty to 13 counts

After affirmative action ruling, medical educators look to 'holistic review'

hotspot

entertainment

hotspot

hotspot